Epizyme Announces Closing of Public Offering of Common Stock

Epizyme Announces Closing of Public Offering of Common Stock

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.

WilmerHale’s lawyers are renowned for their work on mergers and acquisitions, IPOs, private equity deals, strategic alliances and corporate governance matters both domestically and in the EU and China. Healthcare clients, which include Medtronic and PerkinElmer, know us as a one-stop source for solutions to the diverse array of corporate issues they face.

For clients that range from public and private companies to individual entrepreneurs, our corporate lawyers have:

  • Served as issuer counsel or underwriters’ counsel in more than 400 public offerings and Rule 144A placements raising nearly $150 billion since 2006. We have a wide array of capital markets experience, as well as significant commercial finance knowledge.
  • Advised on more than 1,000 M&A deals with a total value in excess of $400 billion since 2006. Our experience ranges from public-public mergers and related SEC, disclosure and fiduciary duty issues to the unique issues presented by sales of private equity and venture-backed private companies.
  • Handled hundreds of strategic alliances, joint ventures, outsourcing and licensing transactions each year, including several strategic alliances that have received industry recognition for their importance. The complexity of these deals often demands deep experience and close collaboration among our corporate, licensing, intellectual property and tax lawyers, as well as our lawyers in the United States, Europe and Asia.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

On September 19, 2017, Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced the closing of its public offering of 10,557,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts. The shares of common stock issued and sold in the offering at the closing include 1,377,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount. The aggregate net proceeds before expenses to Epizyme from the offering are approximately $151.3 million, after deducting underwriting discounts and commissions.

Stuart Falber the led the WilmerHale team representing Epizyme in this transaction, which also included Molly Fox, Emily Gainor and Nils Remole.

Epizyme's press release is available at www.epizyme.com.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel